Phase 2
Completed N=20
A Trial of Vitamin B12 in Septic Shock
Source: ClinicalTrials.gov NCT03783091 ↗Enrolled (actual)
20
Serious AEs
0.0%
Results posted
May 2026
Primary outcomePrimary: Feasibility of Clinical and Protocol Completion — 10; 10 Participants
Summary
This study will randomize 20 septic shock patients to receive either a single 5 gram dose of IV vitamin B12 (Cyanokit® Meridian Medical Technologies, Columbia, MD) versus placebo in addition to standard of care to test the feasibility of completing clinical and laboratory protocols.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Feasibility of Clinical and Protocol Completion |
10; 10 | — |
| SECONDARY Hydrogen Sulfide Concentration |
-13; -3 | — |
| SECONDARY Persistent Organ Dysfunction Syndrome (PODS) |
5; 4 | — |
| SECONDARY Change in Vasopressor Dose |
-28; 10 | — |
| SECONDARY ICU Mortality |
3; 4 | — |
Eligibility Criteria
Inclusion Criteria
- Adult patients at least 18 years of age
- Admitted to the Medical Intensive Care Unit (MICU) service at Froedtert Hospital
- Diagnosis of septic shock, as defined by sepsis-3 criteria
Exclusion Criteria
- History of calcium oxaluria
Data sourced from ClinicalTrials.gov (NCT03783091). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.